TrialLancet (London, England)2018

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

Michael Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.